1
|
Tsvetkov PO, Eyraud R, Ayache S, Bougaev AA, Malesinski S, Benazha H, Gorokhova S, Buffat C, Dehais C, Sanson M, Bielle F, Figarella Branger D, Chinot O, Tabouret E, Devred F. An AI-Powered Blood Test to Detect Cancer Using NanoDSF. Cancers (Basel) 2021; 13:cancers13061294. [PMID: 33803924 PMCID: PMC7999960 DOI: 10.3390/cancers13061294] [Citation(s) in RCA: 2] [Impact Index Per Article: 0.7] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 02/14/2021] [Revised: 03/01/2021] [Accepted: 03/03/2021] [Indexed: 12/12/2022] Open
Abstract
Glioblastoma is the most frequent and aggressive primary brain tumor. Its diagnosis is based on resection or biopsy that could be especially difficult and dangerous in the case of deep location or patient comorbidities. Monitoring disease evolution and progression also requires repeated biopsies that are often not feasible. Therefore, there is an urgent need to develop biomarkers to diagnose and follow glioblastoma evolution in a minimally invasive way. In the present study, we described a novel cancer detection method based on plasma denaturation profiles obtained by a non-conventional use of differential scanning fluorimetry. Using blood samples from 84 glioma patients and 63 healthy controls, we showed that their denaturation profiles can be automatically distinguished with the help of machine learning algorithms with 92% accuracy. Proposed high throughput workflow can be applied to any type of cancer and could become a powerful pan-cancer diagnostic and monitoring tool requiring only a simple blood test.
Collapse
Affiliation(s)
- Philipp O. Tsvetkov
- Faculté des Sciences Médicales et Paramédicales, Inst Neurophysiopathol, CNRS, INP, Aix Marseille Univ, 13005 Marseille, France; (S.M.); (D.F.B.); (O.C.); (E.T.)
- Faculté des Sciences Médicales et Paramédicales, Plateforme Interactome Timone, PINT, Aix Marseille Univ, 13009 Marseille, France
- Correspondence: (P.O.T.); (F.D.)
| | - Rémi Eyraud
- Laboratoire Hubert Curien UMR 5516, UJM-Saint-Etienne, CNRS, University Lyon, 42000 Saint Etienne, France;
| | - Stéphane Ayache
- CNRS, LIS, Aix-Marseille Univ, 13009 Marseille, France; (S.A.); (H.B.)
| | | | - Soazig Malesinski
- Faculté des Sciences Médicales et Paramédicales, Inst Neurophysiopathol, CNRS, INP, Aix Marseille Univ, 13005 Marseille, France; (S.M.); (D.F.B.); (O.C.); (E.T.)
| | - Hamed Benazha
- CNRS, LIS, Aix-Marseille Univ, 13009 Marseille, France; (S.A.); (H.B.)
| | - Svetlana Gorokhova
- MMG, INSERM, Aix-Marseille Univ, 13009 Marseille, France;
- Service de génétique Médicale, Hôpital de La Timone, APHM, 13005 Marseille, France
| | - Christophe Buffat
- Biochemistry and Endocrinology, Hôpital de la Conception, APHM, 13005 Marseille, France;
- MEPHI, IRD, APHM, Aix-Marseille Univ, 13274 Marseille, France
| | - Caroline Dehais
- CNRS, UMR S 1127, Institut du Cerveau et de la Moelle épinière, ICM, Sorbonne Université, Inserm, F-75006 Paris, France; (C.D.); (M.S.); (F.B.)
- Service de Neurologie 2-Mazarin, AP-HP, Hôpitaux Universitaires La Pitié Salpêtrière—Charles Foix, F-75013 Paris, France
| | - Marc Sanson
- CNRS, UMR S 1127, Institut du Cerveau et de la Moelle épinière, ICM, Sorbonne Université, Inserm, F-75006 Paris, France; (C.D.); (M.S.); (F.B.)
- Service de Neurologie 2-Mazarin, AP-HP, Hôpitaux Universitaires La Pitié Salpêtrière—Charles Foix, F-75013 Paris, France
| | - Franck Bielle
- CNRS, UMR S 1127, Institut du Cerveau et de la Moelle épinière, ICM, Sorbonne Université, Inserm, F-75006 Paris, France; (C.D.); (M.S.); (F.B.)
- Département de Neuropathologie, AP-HP, Hôpitaux Universitaires La Pitié Salpêtrière—Charles Foix, F-75013 Paris, France
| | - Dominique Figarella Branger
- Faculté des Sciences Médicales et Paramédicales, Inst Neurophysiopathol, CNRS, INP, Aix Marseille Univ, 13005 Marseille, France; (S.M.); (D.F.B.); (O.C.); (E.T.)
- Service d’Anatomie Pathologique et de Neuropathologie, CHU Timone, APHM, 13005 Marseille, France
| | - Olivier Chinot
- Faculté des Sciences Médicales et Paramédicales, Inst Neurophysiopathol, CNRS, INP, Aix Marseille Univ, 13005 Marseille, France; (S.M.); (D.F.B.); (O.C.); (E.T.)
- Service de Neuro Oncologie, Hopital de La Timone, APHM, 13005 Marseille, France
| | - Emeline Tabouret
- Faculté des Sciences Médicales et Paramédicales, Inst Neurophysiopathol, CNRS, INP, Aix Marseille Univ, 13005 Marseille, France; (S.M.); (D.F.B.); (O.C.); (E.T.)
- Service de Neuro Oncologie, Hopital de La Timone, APHM, 13005 Marseille, France
| | - François Devred
- Faculté des Sciences Médicales et Paramédicales, Inst Neurophysiopathol, CNRS, INP, Aix Marseille Univ, 13005 Marseille, France; (S.M.); (D.F.B.); (O.C.); (E.T.)
- Faculté des Sciences Médicales et Paramédicales, Plateforme Interactome Timone, PINT, Aix Marseille Univ, 13009 Marseille, France
- Correspondence: (P.O.T.); (F.D.)
| |
Collapse
|
2
|
Rosenberg S, Simeonova I, Bielle F, Verreault M, Roux IL, Daniau M, Nadaradjane A, Gleize V, Paris S, Marie Y, Giry M, Polivka M, Branger DF, Aubriot-Lorton MH, Villa C, Vasiljevic A, Lechapt-Zalcman E, Kalamarides M, Mokhtari K, Pagnotta S, Iavarone A, Lasorella A, Huillard E, Sanson M. GENE-54. A NOVEL MUTATION IN PRKCA IS THE MAJOR DRIVER OF CHORDOID GLIOMAS. Neuro Oncol 2017. [DOI: 10.1093/neuonc/nox168.426] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/14/2022] Open
|
3
|
Horwitz M, Dufour C, Leblond P, Bourdeaut F, Faure-Conter C, Bertozzi AI, Delisle MB, Palenzuela G, Jouvet A, Scavarda D, Vinchon M, Padovani L, Gaudart J, Branger DF, Andre N. Embryonal tumors with multilayered rosettes in children: the SFCE experience. Childs Nerv Syst 2016; 32:299-305. [PMID: 26438544 DOI: 10.1007/s00381-015-2920-2] [Citation(s) in RCA: 37] [Impact Index Per Article: 4.6] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 06/22/2015] [Accepted: 09/23/2015] [Indexed: 10/23/2022]
Abstract
PURPOSES The purpose of this study was to retrospectively study embryonal tumors with multilayered rosettes (ETMR), a rare new entity that gathers ETAN-TR (embryonal tumor with abundant neuropil and true rosettes), ependymoblastomas, and medulloepitheliomas, in order to improve their descriptions and try to better define therapeutic modalities. METHODS Patients with ETMR, ETAN-TR, ependymoblastoma, and medulloepithelioma treated in SFCE centres (Société Française de lutte contre les Cancers et les leucémies de l'Enfant et de l'adolescent) since 2000 were collected. Data were retrieved from clinical charts. RESULTS Thirty-eight patients were included in the analysis. Seventeen had an ETAN-TR, 13 had a medulloepithelioma, and 8 had an ETMR. No ependymoblastoma was included. The median age at diagnosis was 31 months (range, 2.8-141 months). The predominant tumor location was supratentorial (66%); 18.4% patients had metastatic lesion. LIN28A expression was positive in 11/11 patients. Amplification of the locus 19q13.42 was positive in 10/12 patients. Thirty patients were treated according to the primitive neuroectodermal tumors of high risk (PNET-HR) protocol. The median time of follow-up was 0.9 years (range 0.1 to 15.3 years). The 1-year event-free survival (EFS) and overall survival (OS) were, respectively, 36% CI 95% (23-55) and 45% CI 95% (31-64). On multivariate analysis, complete surgical resection, radiotherapy, and high-dose chemotherapy were associated with a better overall survival with a relative risk of, respectively, 7.9 CI 95% (2.6-23.5) p < 0.0002, 41.8 CI 95% (9.4-186) p < 0.0001, and 3.5 CI 95% (1.3-9.5) p = 0.012. CONCLUSION Prognosis of ETMR remains dismal despite multimodal therapy. LIN28A immunostaining and 19q13.42 amplification should be systematically done to secure the diagnosis. Complete surgical resection, radiotherapy, and high-dose chemotherapy are associated with better outcome.
Collapse
Affiliation(s)
- Meryl Horwitz
- Department of Pediatric Hematology-Oncology, APHM, La Timone Hospital, 264 rue Saint-Pierre, 13005, Marseille, France.
| | - Christelle Dufour
- Department of Pediatric and Adolescent Oncology, Gustave Roussy Campus, 114, rue Edouard-Vaillant, 94805, Villejuif Cedex, France.
| | - Pierre Leblond
- Department of Pediatric Oncology, Oscar Lambret, 3 rue Frederic Combemale, BP 307, 59020, Lille Cedex, France.
| | - Franck Bourdeaut
- Department of Pediatric Oncology, Institut Curie, 26, rue d'Ulm, 75005, Paris, France. .,INSERM U830, Laboratory of Genetics and Cancer Biology, Institut Curie, Paris, France.
| | - Cécile Faure-Conter
- Department of Pediatrics, Centre Léon Bérard, 28 Prom. Léa et Napoléon Bullukian, 69008, Lyon, France.
| | - Anne-Isabelle Bertozzi
- Department of Hematology-Oncology, Children University Hospital, 330 Avenue de Grande Bretagne, 31300, Toulouse, France.
| | - Marie Bernadette Delisle
- Department of Neuropathology, Toulouse Rangueil University Hospital, 1, avenue du Pr Jean Poulhès, 31400, Toulouse, France.
| | - Gilles Palenzuela
- Department of Pediatric Hematology-Oncology, University Hospital of Montpellier, 191, avenue du doyen Gaston Giraud, 34295, Montpellier cedex, France.
| | - Anne Jouvet
- Department of Pathology and neuropathology, "Pierre Werthmeier" Hospital, Boulevard Pinel, 69677, Bron, France.
| | - Didier Scavarda
- Department of Neurosurgery, APHM, La Timone Hospital, 264 rue Saint-Pierre, 13005, Marseille, France.
| | - Matthieu Vinchon
- Department of Pediatric Neurosurgery, Lille University Hospital, 2 Avenue Oscar Lambret, 59000, Lille, France.
| | - Laetitia Padovani
- Department of Radiation Oncology and Pediatrics, APHM, La Timone Hospital, 264 rue Saint-Pierre, 13005, Marseille, France.
| | - Jean Gaudart
- BIOSTIC, Pôle de Santé Publique, AP-HM, Marseille, 264 rue Saint-Pierre, 13005, Marseille, France. .,UMR912 SESSTIM, Aix-Marseille University, Marseille, France.
| | - Dominique Figarella Branger
- Department of Pathology, APHM, La Timone Hospital, Université Aix-Marseille, 264 rue Saint-Pierre, 13005, Marseille, France.
| | - Nicolas Andre
- Department of Pediatric Hematology-Oncology, APHM, La Timone Hospital, 264 rue Saint-Pierre, 13005, Marseille, France. .,INSERM UMR 911, Centre de Recherche en Oncologie biologique et en Oncopharmacologie, Aix-Marseille University, 264 rue Saint-Pierre, 13005, Marseille, France. .,Department of Pediatric Hematology and Oncology, Children Hospital of La Timone, 264, rue Saint-Pierre, 13005, Marseille, France.
| |
Collapse
|
4
|
Taieb G, Duflos C, Renard D, Audoin B, Kaphan E, Pelletier J, Limousin N, Tranchant C, Kremer S, de Sèze J, Lefaucheur R, Maltête D, Brassat D, Clanet M, Desbordes P, Thouvenot E, Magy L, Vincent T, Faillie JL, de Champfleur N, Castelnovo G, Eimer S, Branger DF, Uro-Coste E, Labauge P. Long-term Outcomes of CLIPPERS (Chronic Lymphocytic Inflammation With Pontine Perivascular Enhancement Responsive to Steroids) in a Consecutive Series of 12 Patients. ACTA ACUST UNITED AC 2012; 69:847-55. [DOI: 10.1001/archneurol.2012.122] [Citation(s) in RCA: 83] [Impact Index Per Article: 6.9] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/14/2022]
|
5
|
Muracciole X, Romain S, Dufour H, Palmari J, Chinot O, Ouafik L, Grisoli F, Branger DF, Martin PM. PAI-1 and EGFR expression in adult glioma tumors: toward a molecular prognostic classification. Int J Radiat Oncol Biol Phys 2002; 52:592-8. [PMID: 11849778 DOI: 10.1016/s0360-3016(01)02699-2] [Citation(s) in RCA: 51] [Impact Index Per Article: 2.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/18/2022]
Abstract
PURPOSE Molecular classification of gliomas is a major challenge in the effort to improve therapeutic decisions. The plasminogen activator system, including plasminogen activator inhibitor type 1 (PAI-1), plays a key role in tumor invasion and neoangiogenesis. Epidermal growth factor receptor (EGFR) is involved in the control of proliferation. The contribution of PAI-1 and EGFR to the survival of gliomas was retrospectively investigated. METHODS AND MATERIALS Fifty-nine adult gliomas treated by neurosurgery and conventional irradiation were analyzed, including 9 low-grade (2) and 50 high-grade (3-4) tumors (WHO classification). PAI-1 was measured on cytosols and EGFR on solubilized membranes using ELISA methods. RESULTS High PAI-1 levels were strongly associated with high histologic grade (p < 0.001) and histologic necrosis (p < 0.001). PAI-1 also correlated positively with patient age (p = 0.05) and negatively with Karnofsky index (p = 0.01). By univariate analysis of the high-grade population, higher PAI-1 (p < 0.0001) and EGFR values (p = 0.02) were associated with shorter overall survival. Only PAI-1 was an independent factor in multivariate analysis. Grade 3 tumors with low PAI-1 (100% 3-year overall survival rate) presented the same clinical outcome as the low-grade tumors. CONCLUSIONS In this prognostic study, PAI-1 and EGFR expression revealed similarities and differences between high-grade gliomas that were not apparent by traditional clinical criteria. These data strongly support that biologic factors should be included in glioma classification and the design of clinical trials to treat more homogeneous populations.
Collapse
|